An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies

J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e828-e831. doi: 10.1111/jdv.17554. Epub 2021 Aug 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dermatologic Agents* / adverse effects
  • Humans
  • Mycoses* / drug therapy
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • ixekizumab

Grants and funding